Facebook Instagram X-twitter Linkedin Youtube Spotify Apple

Clinical Trials

For a quick look at enrolling or soon to be enrolling investigational drug studies in Duchenne and their enrollment criteria, check out our Clinical Trial Cheat Sheet below.
Clinical Trial Cheat Sheet

Clinical Trial Finder

Use this Clinical Trial Finder below that can help provide you with more information regarding clinical trials in Duchenne that that you, your child, or your patient may be eligible for!

Watch Jett Foundation's Mini Satellite Presentation

Emerging Therapies for Duchenne Muscular Dystrophy

Presented by Jean Mah, M.D., Associate Professor of Pediatric Neurology Alberta Children’s Hospital at the 2016 Child Neurology Society Meeting to learn more about these potential therapies!

Latest Duchenne News

July 3, 2026

Sarepta Shares Community Letter and Release Sarepta Announces FDA for Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®

On June 30, 2026, Sarepta Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Applications (sNDAs) for AMONDYS 45® (casimersen)...
Read More
July 3, 2026

Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy

On June 29, 2026, Satellos Bioscience Inc., announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to SAT-3247 for the treatment of Duchenne. Please read...
Read More
July 3, 2026

Solid Biosciences Letter to the Duchenne Community for INSPIRE DUCHENNE and Phase 3 IMPACT DUCHENNE Clinical Studies

On June 26, 2026, Solid Biosciences, Inc. shared a Letter to the Duchenne Community containing updates on the INSPIRE DUCHENNE and Phase 3 IMPACT DUCHENNE clinical studies, regulatory engagement, and...
Read More
July 3, 2026

REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026

On June 24, 2026, REGENXBIO Inc. announced the successful completion of dosing in the confirmatory study of RGX-202, a potential best-in-class gene therapy for Duchenne muscular dystrophy. They also shared...
Read More
June 17, 2026

Italfarmaco Announces Health Canada Acceptance and Priority Review of New Drug Submission for Givinostat as a Duchenne Muscular Dystrophy Treatment

On June 10, 2026, Italfarmaco S.p.A. announced that Health Canada has accepted for review the New Drug Submission (NDS) for givinostat (Duvyzat®) for the treatment of Duchenne muscular dystrophy (DMD)....
Read More
June 4, 2026

Avidity Biosciences Update to the Duchenne Community on Status of DMD45 Investigational Program

On June 4, 2026, Avidity Biosciences shared an update on the planned AOC 1045 clinical trial for individuals with Duchenne muscular dystrophy amenable to exon 45 skipping (DMD45). To view...
Read More